MacroGenics (MGNX) Scheduled to Post Earnings on Tuesday

MacroGenics (NASDAQ:MGNX - Get Free Report) will be announcing its earnings results after the market closes on Tuesday, November 5th. Analysts expect the company to announce earnings of $0.08 per share for the quarter.

MacroGenics (NASDAQ:MGNX - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.42). MacroGenics had a negative return on equity of 146.01% and a negative net margin of 332.47%. The business had revenue of $10.80 million for the quarter, compared to analysts' expectations of $24.14 million. On average, analysts expect MacroGenics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MacroGenics Stock Up 0.9 %

Shares of MGNX stock traded up $0.03 during mid-day trading on Wednesday, reaching $3.37. The company's stock had a trading volume of 408,592 shares, compared to its average volume of 1,495,010. The company's 50 day simple moving average is $3.54 and its 200-day simple moving average is $5.57. MacroGenics has a 12-month low of $2.95 and a 12-month high of $21.88. The firm has a market capitalization of $211.07 million, a PE ratio of -8.54 and a beta of 2.08.

Analyst Upgrades and Downgrades

MGNX has been the subject of several recent research reports. BMO Capital Markets lowered their price objective on shares of MacroGenics from $8.00 to $5.00 and set a "market perform" rating for the company in a research report on Wednesday, August 7th. Guggenheim downgraded shares of MacroGenics from a "buy" rating to a "neutral" rating in a research note on Wednesday, July 31st. Evercore ISI raised shares of MacroGenics to a "strong-buy" rating in a research report on Monday, September 16th. HC Wainwright reaffirmed a "neutral" rating and set a $4.00 target price on shares of MacroGenics in a research report on Wednesday, September 18th. Finally, Barclays reduced their price target on MacroGenics from $14.00 to $9.00 and set an "overweight" rating for the company in a report on Monday, July 29th. Eight analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, MacroGenics presently has an average rating of "Hold" and a consensus target price of $8.11.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.